Metabolic syndrome treatment strategies

Pharmacotherapy

Volumn 26, Issue 12 II, 2006, Pages

  Fujioka, Ken ^a  

^a SCRIPPS CLINIC   (United States)

Author keywords

Lifestyle modification; Metabolic syndrome; Rimonabant; Sibutramine; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HYPOCHOLESTEROLEMIC AGENT; INSULIN SENSITIZING AGENT; RIMONABANT; SIBUTRAMINE;

AGITATION; ANXIETY DISORDER; ARTHRALGIA; BACKACHE; BEHAVIOR MODIFICATION; BRONCHITIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; DEPRESSION; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSPEPSIA; EXERCISE; FATIGUE; FLATULENCE; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; HYPESTHESIA; INFLUENZA; INSOMNIA; LIFESTYLE; METABOLIC SYNDROME X; NAUSEA; RHINOPHARYNGITIS; RISK REDUCTION; SIDE EFFECT; SINUSITIS; SLEEP DISORDER; SMOKING CESSATION; TACHYCARDIA; TREATMENT INDICATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING;

EID: 33845253877     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12part2.222s     Document Type: Conference Paper

References (11)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285(19):2486-97.
2. Grundy SM, Cleeman JI, Daniels SR, et al, for the American Heart Association, and the National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005;112:2735-52. (Errata in Circulation 2005;112(17):e297-8.)
3. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N EnglJ Med 2002;346(6):393-403.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention study investigators. N Engl J Med 2000;342(3):145-53. (Errata in N Engl J Med 2000;342(10):748, N Engl J Med 2000;342(18):1376).
5. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93.
6. King AC, Haskell WL, Young DR, Oka RK, Stefanick ML. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation 1995;91:2596-604.
7. James WPT, Astrup A, Finer N. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet 2000;356:2119-25.
8. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America. A randomized controlled trial. JAMA 2006;295(7):761-75. (Erratum in JAMA 2006;295(11):1252.)
9. Van Gaal LF, Rissanen AM, Scheen AJ, Rossner S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experienced from the RIO-Europe study. Lancet 2005;365:1389-97.
10. Despres JP, Golay A, Sjostrom L, for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353(20):2121-34.
11. European Medicines Agency. Acomplia. Available from http://www.emea.eu. int/humandocs/Humans/EPAR/acomplia/acomplia.htm. Accessed August 6, 2006.